Danceswithhorses,

Amarin's 25% RRR in REDUCE-IT was in 5-point MACE, not 3-point MACE. At this point, we don't know which MACE events were driving this RRR. Full data will be presented in about 6 weeks at AHA. Is it primarily "soft" events, or the more strict 3-point MACE (CVD death, non-fatal MI, non-fatal stroke)? And importantly, any effect on CVD death? If little to no effect on 3-point MACE, Vascepa may be a bust. Based on Amarin's 12-week long MARINE and ANCHOR trials, I'm not too impressed by the triglyceride or hsCRP lowering. Vascepa may be having some other cardioprotective effects aside from TG or hsCRP lowering, but the modest ~25% TG reduction in ANCHOR still leaves patients in the hypertriglyeridemic range and little to no effect on hsCRP. Very little effect of the 2g/day Vascepa in ANCHOR, only 4g/day Vascepa. The placebo group in ANCHOR was dosed with mineral oil and there seems to be a trend of increased LDL-C, hsCRP, and TG in the placebo group. 2g/day Vascepa in ANCHOR also got 2g/day mineral oil. So claims of success in REDUCE-IT may be partially inflated due to some undesirable effects of the mineral oil placebo (horrible choice of control oil, IMO). Full data for REDUCE-IT at AHA will be important to scrutinize on many fronts. 

BearDownAZ